Recombinant Human CDK6 Protein，His

Cyclin-dependent kinase 6 (CDK6) is a critical serine/threonine kinase that plays a vital role in regulating the cell cycle, particularly in transitioning from the G1 phase to the S phase. Its activity is tightly regulated by cyclins and CDK inhibitors, making it an important target for cancer research, especially in tumors with dysregulated cell cycle progression. Overexpression or constant activation of CDK6 has been implicated in various malignancies, including leukemia, breast cancer, and glioblastoma, where it contributes to uncontrolled cellular proliferation. Recent studies have highlighted the potential of CDK6 as a therapeutic target, leading to the development of selective CDK6 inhibitors that can effectively hinder tumor growth while sparing normal cells. The study of recombinant CDK6 proteins provides valuable insights into its structure, function, and interaction with other cellular proteins, facilitating the identification of novel inhibitors and advancing our understanding of CDK6's role in oncogenesis. Through structural biology techniques and biophysical analyses, researchers aim to delineate the molecular mechanisms by which CDK6 contributes to cancer and to explore potential therapeutic strategies aimed at modulating its activity. As our understanding of CDK6 evolves, the development of precise and effective treatment options based on CDK6 modulation holds promise for improving cancer therapeutics and patient outcomes.